The current financial score of IDEXX Laboratories Inc is 8.66. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.22B, representing a year-over-year increase of 9.66%, while its net profit experienced a year-over-year increase of 15.11%.
The current valuation score of IDEXX Laboratories Inc is 7.56. Its current P/E ratio is 41.67, which is 52.08% below the recent high of 63.37 and 20.62% above the recent low of 33.08.
The current earnings forecast score of IDEXX Laboratories Inc is 7.88. The average price target is 706.03, with a high of 805.00 and a low of 472.45.
The current price momentum score of IDEXX Laboratories Inc is 3.57. Currently, the stock price is trading between the resistance level at 594.11 and the support level at 523.74, making it suitable for range-bound swing trading.
The current institutional shareholding score of IDEXX Laboratories Inc is 10.00. The latest institutional shareholding proportion is 96.54%, representing a quarter-over-quarter decrease of 5.07%. The largest institutional shareholder is Jerome Dodson | PARNX, holding a total of 31.68K shares, representing 0.05% of shares outstanding, with 9.04% decrease in holdings.
The current risk assessment score of IDEXX Laboratories Inc is 8.04. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.